Literature DB >> 10828959

Conformational difference between PDE4 apoenzyme and holoenzyme.

F Laliberté1, Y Han, A Govindarajan, A Giroux, S Liu, B Bobechko, P Lario, A Bartlett, E Gorseth, M Gresser, Z Huang.   

Abstract

The type 4 cAMP-specific phosphodiesterases (PDE4s) are Mg(2+)-dependent hydrolases that catalyze the hydrolysis of 3', 5'-cAMP to AMP. Previous studies indicate that PDE4 exists in two conformations that bind the inhibitor rolipram with affinities differing by more than 100-fold. Here we report that these two conformations are the consequence of PDE4 binding to its metal cofactor such as Mg(2+). Using a fluorescence resonance energy transfer (FRET)-based equilibrium binding assay, we identified that L-791,760, a fluorescent inhibitor, binds to the apoenzyme (free enzyme) and the holoenzyme (enzyme bound to Mg(2+)) with comparable affinities (K(d) approximately 30 nM). By measuring the displacement of the bound L-791,760, we have also identified that other inhibitors bind differentially with the apoenzyme and the holoenzyme depending upon their structure. CDP-840, SB-207499, and RP-73401 bind preferentially to the holoenzyme. The conformational-sensitive inhibitor (R)-rolipram binds to the holoenzyme and apoenzyme with affinities (K(d)) of 5 and 300 nM, respectively. In contrast to its high affinity (K(d) approximately 2 microM) and active holoenzyme complex, cAMP binds to the apoenzyme nonproductively with a reduced affinity (K(d) approximately 170 microM). These results demonstrate that cofactor binding to PDE4 is responsible for eliciting its high-affinity interaction with cAMP and the activation of catalysis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10828959     DOI: 10.1021/bi992432w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  5 in total

1.  Assessing the emetic potential of PDE4 inhibitors in rats.

Authors:  A Robichaud; C Savoie; P B Stamatiou; N Lachance; P Jolicoeur; R Rasori; C C Chan
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis.

Authors:  Annette Robichaud; Panagiota B Stamatiou; S-L Catherine Jin; Nicholas Lachance; Dwight MacDonald; France Laliberté; Susana Liu; Zheng Huang; Marco Conti; Chi-Chung Chan
Journal:  J Clin Invest       Date:  2002-10       Impact factor: 14.808

3.  Enantiomer discrimination illustrated by the high resolution crystal structures of type 4 phosphodiesterase.

Authors:  Qing Huai; Yingjie Sun; Huanchen Wang; Dwight Macdonald; Renée Aspiotis; Howard Robinson; Zheng Huang; Hengming Ke
Journal:  J Med Chem       Date:  2006-03-23       Impact factor: 7.446

Review 4.  PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization.

Authors:  Miles D Houslay; David R Adams
Journal:  Biochem J       Date:  2003-02-15       Impact factor: 3.857

Review 5.  Phosphodiesterase-4 inhibitors in the treatment of inflammatory lung disease.

Authors:  Domenico Spina
Journal:  Drugs       Date:  2003       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.